(thirdQuint)Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab.

 PRIMARY OBJECTIVES: I.

 Explore the effectiveness of a menadione topical lotion to the face to prevent cutaneous and psychological discomfort from epidermal growth factor receptor (EGFR) inhibitors.

 SECONDARY OBJECTIVES: I.

 Explore the adverse event profile of a menadione topical lotion to the face to prevent rash from EGFR inhibitors.

 II.

 Explore whether rash or adverse events worsen over a 4 week period after this 4-week intervention.

 OUTLINE: Patients are randomized to 1 of 2 treatment arms.

 ARM I: Patients apply menadione topical lotion twice daily (BID) for 28 days.

 ARM II: Patients apply topical placebo lotion BID for 28 days.

 After completion of study treatment, patients are followed up for 4 weeks.

.

 Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab@highlight

This clinical trial studies menadione topical lotion in treating skin discomfort and psychological distress in patients with cancer receiving panitumumab, erlotinib hydrochloride, or cetuximab.

 Menadione topical lotion may prevent rash or other skin discomfort and help alleviate psychological distress and pain in patients receiving treatment with panitumumab, erlotinib hydrochloride, or cetuximab